Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O60303
UPID:
KATIP_HUMAN
Alternative names:
-
Alternative UPACC:
O60303; A7E2C2
Background:
Katanin-interacting protein plays a pivotal role in cellular dynamics, influencing the stability of microtubules. This is achieved possibly through its interaction with the microtubule-severing katanin complex, highlighting its critical function in cellular architecture and division.
Therapeutic significance:
Linked to Joubert syndrome 26, a disorder characterized by cerebellar ataxia and a host of other neurological symptoms, the study of Katanin-interacting protein offers a promising avenue for therapeutic intervention. Understanding the role of Katanin-interacting protein could open doors to potential therapeutic strategies.